Mokari Atabak sold $2.8M of CORT

Mokari Atabak (Chief Financial Officer) sold 40,000 shares of CORCEPT THERAPEUTICS INC (CORT) at $70.00 ($2.80M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mokari Atabak
Published Jun 3, 2026, 11:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 11:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The main tradable element is potential short-term sentiment impact from insider selling; however, the pre-arranged 10b5-1 plan generally lowers interpretive weight.

02

Market read

A routine 10b5-1 insider sale disclosure; likely low incremental fundamental impact.

03

What to watch

Form 4s often aggregate multiple scheduled trades; without context on prior/next tranche sizes, the incremental signal is weak.

Relevance 6/10Novelty 3/10Timing: After-hours/filing disclosure dated June 3 for a June 1 sale

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Corcept Therapeutics, reporting an open-market sale by the CFO.

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

Corcept Therapeutics CFO Mokari Atabak sold 40,000 shares in an open-market transaction disclosed via SEC Form 4 on June 1 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment/positioning.

Evidence & confidence

The filing is an ownership-change disclosure (Form 4) with a stated pre-arranged 10b5-1 plan, which typically dampens interpretive value versus discretionary selling.

Market effects

Limited read-through to biotech/pharma sector fundamentals; this is company-specific insider activity.

No clear regional spillover expected from a single Form 4 transaction.

Minimal global relevance; disclosure is routine and not tied to operational or regulatory events.

Counterpoint

Because the sale is on a 10b5-1 plan, it may reflect routine liquidity needs rather than negative expectations; any dip could be overdone.

Key entities

  • Corcept Therapeutics Inc

    Subject of the Form 4 insider transaction disclosure.

  • Mokari Atabak

    Chief Financial Officer who sold 40,000 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.